TrialFrontiers in immunology2025

Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer.

Lin Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.